Expression profiling and individualisation of treatment for ovarian cancer
Expression profiling and individualisation of treatment for ovarian cancer
复制标题
DOI：
10.1016/j.coph.2006.02.007
复制
发表时间：
2006-08-01
影响因子：
4
通讯作者：
Kaye, Stan B.
中科院分区：
文献类型：
--
作者：
Agarwal, Roshan;Kaye, Stan B.
卵巢癌是妇科癌症相关死亡的最常见原因。患有这种疾病的患者通常接受手术，然后进行铂-紫杉烷化疗，复发时进行额外的化疗。虽然晚期癌症患者的预后很差-五年生存率仅为30-40% -但个体患者的预后范围很广。迄今为止，临床病理变量，如年龄，阶段，等级，组织学，减积状态和化疗反应继续提供治疗决策的基础上，为个别患者。免疫组织化学标记物和p53突变状态的信息已被广泛评估卵巢癌，但尚未被证明是足够的信息，影响临床决策的常规基础上。最近出现的表达谱提供了一个新的动力，以确定临床有用的预后标志物。通过基于微阵列的分析实现个性化医疗的雄心似乎是现实的，但在充分实现这一潜力之前，需要对大型统一队列进行进一步研究。
Ovarian cancer is the commonest cause of gynaecological cancer-related mortality. Patients with this disease generally undergo surgery followed by platinum-taxane chemotherapy, with additional chemotherapy at relapse. Although the prognosis for patients with advanced cancer is poor - a five-year survival of only 30-40% - there is a wide range of outcomes for individual patients. To date, clinico-pathological variables such as age, stage, grade, histology, debulking status and response to chemotherapy continue to provide the basis on which treatment decisions are made for individual patients. Immunohistochemical markers and information on p53 mutation status have been extensively evaluated in ovarian cancer, but have not yet been shown to be sufficiently informative to influence clinical decisions on a routine basis. The recent advent of expression profiling has provided a new impetus to identifying clinically useful prognostic markers. The ambition of personalised medicine through microarray-based profiling appears to be realistic, but further studies on large uniform cohorts are needed before this potential is fully realised.